Afrezza® INHALE-1 Study in Pediatrics
Recruiting
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine in combination with a basal insulin (i.e., the Rapid-acting Insulin Analog [RAA] injection group) in pediatric subjects with type 1 or type 2 diabetes mellitus. Following 26 weeks of randomized treatment (i.e., Afrezza or RAA injection combined with a basal insulin), all... Read More
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
11/07/2023
Locations: Nemours Children's Hospital, Delaware, Wilmington, Delaware
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
Recruiting
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
10/16/2023
Locations: Nemours Children's Health - Delaware, Wilmington, Delaware
Conditions: Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
Recruiting
The objective of this clinical trial is to assess whether ladarixin treatment is effective in preserving beta-cell function and delaying the progression of type 1 diabetes (T1D) in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated.
Gender:
All
Ages:
Between 14 years and 45 years
Trial Updated:
10/04/2023
Locations: Christiana Care Endocrinology Specialists, Newark, Delaware
Conditions: New-onset type1 Diabetes
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
Recruiting
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
Gender:
All
Ages:
30 years and above
Trial Updated:
06/16/2023
Locations: HealthCore, Inc., Wilmington, Delaware
Conditions: Diabetes Mellitus, Type 2